Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Interest & Investment Income: 2016-2025

Historic Interest & Investment Income for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $5.9 million.

  • Ultragenyx Pharmaceutical's Interest & Investment Income fell 45.36% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year decrease of 21.04%. This contributed to the annual value of $36.5 million for FY2024, which is 36.79% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Interest & Investment Income of $5.9 million as of Q3 2025, which was up 1.19% from $5.8 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Interest & Investment Income high stood at $10.7 million for Q3 2024, and its period low was $408,000 during Q3 2021.
  • In the last 3 years, Ultragenyx Pharmaceutical's Interest & Investment Income had a median value of $6.8 million in 2025 and averaged $7.4 million.
  • In the last 5 years, Ultragenyx Pharmaceutical's Interest & Investment Income slumped by 78.11% in 2021 and then skyrocketed by 1,308.64% in 2022.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Interest & Investment Income stood at $440,000 in 2021, then spiked by 1,308.64% to $6.2 million in 2022, then spiked by 38.00% to $8.6 million in 2023, then increased by 11.66% to $9.6 million in 2024, then crashed by 45.36% to $5.9 million in 2025.
  • Its Interest & Investment Income stands at $5.9 million for Q3 2025, versus $5.8 million for Q2 2025 and $6.8 million for Q1 2025.